PER

2.35%

8.7¢ percheron therapeutics limited

Thanks Wayne, Something more recent.... Capricor came out in May...

First 7 Last

Share
Profile

Follow
Uboy

4,683 Posts.

1086

06/10/20

11:07

Post #: 47876945
Share

Originally posted by waynesworld ↑

From the patients and parents perspective it doesn't matter whether the therapy is exon-skipping or gene therapy, whether its steroids or other anti inflammatory treatments. What actually matters is whether the medication is effective in improving quality of life and increasing life span without nasty side effects. Outside of a cure, its the ability to be self sufficient in the little things of life and gain enjoyment from daily activities that we all take for granted. So, PUL 2.0 is a proxy measurement for all those things.

Just as ANP can compare the mean change for the nine boys in their Phase II trial against the Rome Cohort, so too can Pharma/Biotech compare their drugs performance against ATL1102. There is a presentation Performance of Upper Limb Measure: PUL 2.0 made to the PPMD Conference in June 2016. Just for some context, before PUL 2.0 there was PUL 1.2; simply put PUL 2.0 is a refinement of PUL 1.2 to improve PUL's measurement properties and ease and clarity of testing. I wanted to highlight one slide titled Studies Using PUL. Its a list of Pharma/Biotech including Sarepta who use either PUL 1.2 or PUL 2.0 in studies. Remember this is from a presentation in 2016 so it would be interesting to see an update.

I mention the slide because it highlights the importance of PUL as an endpoint. I suspect that the announcement by ANP of comparison with a matched natural history control is of far greater importance than at first glance: the audience includes shareholders but will speak more loudly to advocacy groups, clinicians and pharmaceutical and biotech companies operating in the space.

It also begs the following question. What would be the PUL 2.0 results once an optimal dose for ATL1102 is established and what would be the PUL 2.0 results in combination therapy using ATL1102 and exon skipping or gene therapy drug?

Expand

Thanks Wayne,

Something more recent....

Capricor came out in May with their P2 PUL2.0 results: a mean loss in PUL2 over the 12 months of -1.3

Now the Rome cohort with natural history PUL mean was -2.0

ATL1102 comes in at +0.9 in only 6 months.

Capricor have a meeting with FDA later this year re next steps....guessing they're trying Fast Track route to use P2 results.

Our data is good!

ANP Price at posting: 10.5¢ Sentiment: Buy Disclosure: Held
11 Upvote

1 Great analysis

Reply

Top Stories

EMD

Emyria's Empax Centre chosen for mental health clinical trial

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

STX

Strike Energy secures $153 million for Perth Basin gas projects

FHE

Frontier Energy achieves key milestone for Waroona energy project

AML

Cultural heritage agreement puts Walford Creek exploration back on the map

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

SBW

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

RDN

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

BRX

Belararox delineates another porphyry in Argentina at Tambo South

There are more pages in this discussion • 74 more messages in this thread...

First 7 Last

Add PER (ASX) to my watchlist

(20min delay)
Last 8.7¢		Change 0.002(2.35%)		Mkt cap ! $78.43M

Open	High	Low	Value	Volume
8.6¢	8.9¢	8.5¢	$53.40K	614.3K

Buyers (Bids)

No.	Vol.	Price($)
1	49999	8.7¢

Sellers (Offers)

Price($)	Vol.	No.
8.9¢	67263	1

View Market Depth

No.	Vol.	Price($)
1	49999	0.087
2	500872	0.085
2	262571	0.084
1	10000	0.083
2	120000	0.082

Price($)	Vol.	No.
0.089	67263	1
0.090	546175	2
0.091	108000	1
0.092	135429	2
0.093	175642	3

Last trade - 16.10pm 21/06/2024 (20 minute delay)

PER (ASX) Chart

Thanks Wayne, Something more recent.... Capricor came out in May...

Emyria's Empax Centre chosen for mental health clinical trial

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Strike Energy secures $153 million for Perth Basin gas projects

Frontier Energy achieves key milestone for Waroona energy project

Cultural heritage agreement puts Walford Creek exploration back on the map

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Belararox delineates another porphyry in Argentina at Tambo South

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks Wayne, Something more recent.... Capricor came out in May...

Top Stories

Emyria's Empax Centre chosen for mental health clinical trial

With financials holding the fort, materials must step up with some heavy lifting to stimulate stocks

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

Strike Energy secures $153 million for Perth Basin gas projects

Frontier Energy achieves key milestone for Waroona energy project

Cultural heritage agreement puts Walford Creek exploration back on the map

ASX Market Update: Shares fall flat as GYG soars on debut | 20 June, 2024

Shekel Brainweigh CEO Nir Leshem weighs in on AI adoption ahead of FY25

If you thought lithium was dead, think again. The Pilbara will be central to the next upswing

Belararox delineates another porphyry in Argentina at Tambo South

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News